| 초록 |
A thrombus is a biological response against blood vessel injuries in response to high concentration of hydrogen peroxide(H2O2). Nonetheless, an excessive formation of the coagulant can induce thrombotic diseases. Ethyl salicylate(ESA), a major component of aspirin, is an potent anti-thrombotic drugs. However, because of its short half-life, ESA can’t target the inflammatory sites. To overcome these drawbacks, we developed the thrombus targeting aspirin polyconjugate particles(T-APP). T-APP can target the thrombosed vessels by using the targeting ligand and enhance the therapeutic efficacy by suppressing anti-inflammatory cytokines and inhibiting platelet activation in H2O2-activatable manner. In mouse models of arterial thrombosis, we found that the T-APP suppressed thrombus formation and exerted stronger anti-platelet activity than ESA. Therefore, we believe T-APP hold promising translational potential as theranostic agents for H2O2-associated cardiovascular diseases. |
